Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer
Related Experiment Video
Updated: Dec 6, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Yoshitaka Saito1, Yoh Takekuma1, Masaki Kobayashi2
1Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
Purpose:
Gefitinib is one of the standard treatments for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. It has been reported that acid suppressants (AS) decrease the anti-tumor effect of gefitinib by reducing its solubility. AS is sometimes necessary in cancer patients; however, previous reports have not shown the most compatible AS with gefitinib administration in cancer patients. This study was conducted to determine if histamine type 2 receptor antagonists (H2RAs) can affect the anti-tumor efficacy of gefitinib.
Methods:
Eighty-seven patients with NSCLC who were administered gefitinib were retrospectively investigated. Patients who were co-administered H2RA were compared with non-AS control patients. H2RA was administered once a day at about 3-5 or 8-12 h after gefitinib intake. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints were overall survival (OS), overall response rate (ORR), and adverse effects.
Results:
Median PFS in H2RA group and control group was 8.0 months and 9.0 months, respectively, with no significant difference (p = 0.82). The incidence of liver dysfunction was significantly less in patients administered H2RA, whereas there were no differences between the two groups with regard to skin toxicity and diarrhea. Multivariate analysis suggested that H2RA co-administration is not a risk factor for worse PFS and OS (hazard ratio of 0.95, 0.86; 95% confidence interval of 0.60-1.48, 0.52-1.43; p = 0.82 and 0.60, respectively).
Conclusion:
This study demonstrated that concomitant administration of H2RA with gefitinib does not affect the efficacy of gefitinib.
Insights
Histamine type 2 receptor antagonists (H2RAs) do not impact the anti-tumor efficacy of gefitinib in non-small cell lung cancer (NSCLC) patients. This study found no significant difference in progression-free survival when H2RAs were co-administered with gefitinib.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gefitinib is a standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
- Acid suppressants (AS) may reduce gefitinib's efficacy by decreasing its solubility.
- The compatibility of different AS with gefitinib requires further investigation.
Purpose of the Study:
- To evaluate the effect of histamine type 2 receptor antagonists (H2RAs) on the anti-tumor efficacy of gefitinib in NSCLC patients.
- To determine if H2RAs can be safely co-administered with gefitinib without compromising treatment outcomes.
Main Methods:
- Retrospective analysis of 87 NSCLC patients treated with gefitinib.
- Comparison of patients co-administered H2RA with a control group not receiving AS.
- Primary endpoint: progression-free survival (PFS); Secondary endpoints: overall survival (OS), overall response rate (ORR), and adverse effects.
Main Results:
- Median PFS was 8.0 months for the H2RA group and 9.0 months for the control group (p=0.82).
- H2RA co-administration was associated with significantly less liver dysfunction.
- No significant differences were observed in skin toxicity, diarrhea, PFS, or OS between groups.
Conclusions:
- Concomitant administration of H2RA with gefitinib does not negatively affect gefitinib's efficacy.
- H2RAs may reduce the incidence of liver dysfunction in patients receiving gefitinib.
- H2RAs are not a risk factor for worse PFS or OS when co-administered with gefitinib.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Targeted Cancer Therapies
There are several types of targeted therapies against...